Choice of therapy for patients with waldenström macroglobulinemia

Journal of Clinical Oncology

Volumn 31, Issue 3, 2013, Pages 291-293

  Ghobrial, Irene M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; BENDAMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; IMMUNOMODULATING AGENT; MYELOID DIFFERENTIATION FACTOR 88; NUCLEOSIDE ANALOG; OPROZOMIB; PREDNISONE; PROTEASOME INHIBITOR; RITUXIMAB; VINCRISTINE;

ADD ON THERAPY; ALGORITHM; CHEMOTHERAPY; CLINICAL TRIAL; DRUG APPROVAL; EDITORIAL; GENE SEQUENCE; HUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; WALDENSTROEM MACROGLOBULINEMIA;

CLINICAL TRIALS AS TOPIC; HUMANS; WALDENSTROM MACROGLOBULINEMIA;

EID: 84873394276     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.6177     Document Type: Editorial

References (42)

1. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, et al: Waldenström's macroglobulinemia: Clinical features, complications, and management. J Clin Oncol 18:214-226, 2000 (Pubitemid 30036355)
2. Ghobrial IM, Witzig TE: Waldenström macroglobulinemia. Curr Treat Options Oncol 5:239-247, 2004
3. Dimopoulos MA, Kyle RA, Anagnostopoulos A, et al: Diagnosis and management of Waldenstrom's macroglobulinemia. J Clin Oncol 23:1564-1577, 2005
4. Owen RG, Treon SP, Al-Katib A, et al: Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 30:110-115, 2003 (Pubitemid 36506291)
5. Zhang Y, Roccaro AM, Rombaoa C, et al: LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas. Blood 120:1678-1686, 2012
6. Treon SP, Xu L, Yang G, et al: MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med 367:826-833, 2012
7. Braggio E, Dogan A, Keats JJ, et al: Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities. Mod Pathol 25:651-660, 2012
8. Elsawa SF, Novak AJ, Ziesmer SC, et al: Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity. Blood 118:5540-5549, 2011
9. Roccaro AM, Sacco A, Chen C, et al: MicroRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia. Blood 113:4391-4402, 2009
10. Treon SP, Gertz MA, Dimopoulos M, et al: Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. Blood 107:3442-3446, 2006
11. Dimopoulos MA, Gertz MA, Kastritis E, et al: Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol 27:120-126, 2009
12. Issa GC, Leblebjian H, Roccaro AM, et al: New insights into the pathogenesis and treatment of Waldenstrom macroglobulinemia. Curr Opin Hematol 18:260-265, 2011
13. Treon SP, Patterson CJ, Kimby E, et al: Advances in the biology and treatment of Waldenstrom's macroglobulinemia: A report from the 5th International Workshop on Waldenstrom's Macroglobulinemia, Stockholm, Sweden. Clin Lymphoma Myeloma 9:10-15, 2009
14. Treon SP: How I treat Waldenström macroglobulinemia. Blood 114:2375-2385, 2009
15. Kyle RA, Greipp PR, Gertz MA, et al: Waldenström's macroglobulinaemia: A prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol 108:737-742, 2000 (Pubitemid 30304504)
16. Leblond V, Lévy V, Maloisel F, et al: Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide- doxorubicin-prednisone in 92 patients with Waldenströ m macroglobulinemia in first relapse or with primary refractory disease. Blood 98:2640-2644, 2001
17. Buske C, Hoster E, Dreyling M, et al: The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: Results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia 23:153-161, 2009
18. Cheson BD, Rummel MJ: Bendamustine: Rebirth of an old drug. J Clin Oncol 27:1492-1501, 2009
19. Leblond V, Johnson S, Chevret S, et al: Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol 31:301-307, 2013
20. Tedeschi A, Benevolo G, Varettoni M, et al: Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: An effective but myelosuppressive regimen to be offered to patients with advanced disease. Cancer 118:434-443, 2012
21. Gruson B, Ghomari K, Beaumont M, et al: Long-term response to rituximab and fludarabine combination in IgM anti-myelin-associated glycoprotein neuropathy. J Peripher Nerv Syst 16:180-185, 2011
22. Treon SP, Branagan AR, Ioakimidis L, et al: Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia. Blood 113:3673-3678, 2009
23. Leblond V, Choquet S: Fludarabine in Waldenstrom's macroglobulinemia. Semin Oncol 30:239-242, 2003 (Pubitemid 36506317)
24. Dimopoulos MA, Hamilos G, Efstathiou E, et al: Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamide. Leuk Lymphoma 44:993-996, 2003 (Pubitemid 36416998)
25. Treon SP, Emmanouilides C, Kimby E, et al: Extended rituximab therapy in Waldenström's macroglobulinemia. Ann Oncol 16:132-138, 2005 (Pubitemid 40124490)
26. Gertz MA, Rue M, Blood E, et al: Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): An Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma 45:2047-2055, 2004 (Pubitemid 39232853)
27. Dimopoulos MA, Zervas C, Zomas A, et al: Extended rituximab therapy for previously untreated patients with Waldenström's macroglobulinemia. Clin Lymphoma 3:163-166, 2002 (Pubitemid 36113687)
28. Tam CS, Wolf M, Prince HM, et al: Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma. Cancer 106:2412-2420, 2006 (Pubitemid 43791961)
29. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al: Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 25:3344-3349, 2007 (Pubitemid 47325621)
30. Roccaro AM, Sacco A, Leleu X, et al: Role of proteasome inhibition in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma 9:94-96, 2009
31. Ghobrial IM, Xie W, Padmanabhan S, et al: Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström macroglobulinemia. Am J Hematol 85:670-674, 2010
32. Chen CI, Kouroukis CT, White D, et al: Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: A phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1570-1575, 2007 (Pubitemid 46733084)
33. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al: Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib. Haematologica 90:1655-1658, 2005 (Pubitemid 41814990)
34. Ghobrial IM, Hong F, Padmanabhan S, et al: Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol 28:1422-1428, 2010
35. Treon SP, Ioakimidis L, Soumerai JD, et al: Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol 27:3830-3835, 2009
36. Dimopoulos MA, Chen C, Kastritis E, et al: Bortezomib as a treatment option in patients with Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk 10:110-117, 2010
37. Sacco A, Aujay M, Morgan B, et al: Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's macroglobulinemia. Clin Cancer Res 17:1753-1764, 2011
38. Roccaro AM, Sacco A, Aujay M, et al: Selective inhibition of chymotrypsinlike activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia. Blood 115:4051-4060, 2010
39. Ghobrial IM, Gertz M, Laplant B, et al: Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol 28:1408-1414, 2010
40. Treon SP, Yang G, Hanzis C, et al: Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia. Br J Haematol 154:223-228, 2011
41. Gertz MA, Abonour R, Heffner LT, et al: Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: A follow-up of the Eastern Cooperative Oncology Group E3A98 trial. Br J Haematol 147:677-680, 2009
42. Leleu X, Soumerai J, Roccaro A, et al: Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. J Clin Oncol 27:250-255, 2009